(CLARI) Clariane SE - Overview
Stock: Nursing Homes, Home Care, Assisted Living, Rehabilitation, Outpatient Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.8% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 38.96 |
| Character TTM | |
|---|---|
| Beta | -0.079 |
| Beta Downside | 0.042 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.04% |
| CAGR/Max DD | -0.06 |
Description: CLARI Clariane SE January 16, 2026
Clariane SE (ticker CLARI) operates a diversified portfolio of long-term care and short-stay nursing homes across France, Germany, Benelux, Italy, Spain, and the United Kingdom, delivering both residential and outpatient health services.
Beyond traditional nursing facilities, the group runs diagnosis outpatient programs, full-hospitalisation services, day-hospital and consultation clinics, post-acute rehabilitation centres, mental-health clinics, and a network of hospital-at-home and community-nursing providers, as well as assisted-living and shared-housing residences.
The company, originally founded as Korian in 2001 and rebranded to Clariane SE in June 2023, remains headquartered in Paris, France, and is classified under the GICS sub-industry “Health Care Facilities.”
Key operational metrics (FY 2023) include ~120,000 beds under management, an occupancy rate of 86 % (above the European senior-care average of ~81 %), and revenue growth of 4.2 % YoY, driven in part by demographic aging in the EU and increasing public spending on long-term care.
For a deeper, data-rich analysis of Clariane’s valuation assumptions and scenario modeling, the ValueRay platform offers a transparent, model-based view worth exploring.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -86.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.46 > 1.0 |
| NWC/Revenue: -11.24% < 20% (prev -11.76%; Δ 0.53% < -1%) |
| CFO/TA 0.06 > 3% & CFO 877.7m > Net Income -86.6m |
| Net Debt (7.46b) to EBITDA (1.90b): 3.93 < 3 |
| Current Ratio: 0.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (355.8m) vs 12m ago 144.4% < -2% |
| Gross Margin: 26.30% > 18% (prev 0.19%; Δ 2611 % > 0.5%) |
| Asset Turnover: 53.62% > 50% (prev 49.70%; Δ 3.92% > 0%) |
| Interest Coverage Ratio: 0.82 > 6 (EBITDA TTM 1.90b / Interest Expense TTM 489.1m) |
Altman Z'' 0.66
| A: -0.06 (Total Current Assets 2.09b - Total Current Liabilities 2.98b) / Total Assets 14.41b |
| B: 0.14 (Retained Earnings 2.07b / Total Assets 14.41b) |
| C: 0.03 (EBIT TTM 403.3m / Avg Total Assets 14.80b) |
| D: 0.39 (Book Value of Equity 4.14b / Total Liabilities 10.49b) |
| Altman-Z'' Score: 0.66 = B |
Beneish M -3.55
| DSRI: 0.69 (Receivables 830.2m/1.14b, Revenue 7.93b/7.55b) |
| GMI: 0.71 (GM 26.30% / 18.78%) |
| AQI: 1.04 (AQ_t 0.40 / AQ_t-1 0.39) |
| SGI: 1.05 (Revenue 7.93b / 7.55b) |
| TATA: -0.07 (NI -86.6m - CFO 877.7m) / TA 14.41b) |
| Beneish M-Score: -3.55 (Cap -4..+1) = AAA |
What is the price of CLARI shares?
Over the past week, the price has changed by +0.73%, over one month by +2.79%, over three months by +12.29% and over the past year by +51.10%.
Is CLARI a buy, sell or hold?
What are the forecasts/targets for the CLARI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 16.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4 | 4.2% |
CLARI Fundamental Data Overview February 03, 2026
P/E Forward = 36.1011
P/S = 0.2558
P/B = 0.3766
Revenue TTM = 7.93b EUR
EBIT TTM = 403.3m EUR
EBITDA TTM = 1.90b EUR
Long Term Debt = 3.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.40b EUR (from shortTermDebt, last quarter)
Debt = 8.21b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.46b EUR (from netDebt column, last quarter)
Enterprise Value = 9.48b EUR (1.36b + Debt 8.21b - CCE 84.0m)
Interest Coverage Ratio = 0.82 (Ebit TTM 403.3m / Interest Expense TTM 489.1m)
EV/FCF = 14.47x (Enterprise Value 9.48b / FCF TTM 655.2m)
FCF Yield = 6.91% (FCF TTM 655.2m / Enterprise Value 9.48b)
FCF Margin = 8.26% (FCF TTM 655.2m / Revenue TTM 7.93b)
Net Margin = -1.09% (Net Income TTM -86.6m / Revenue TTM 7.93b)
Gross Margin = 26.30% ((Revenue TTM 7.93b - Cost of Revenue TTM 5.85b) / Revenue TTM)
Gross Margin QoQ = 30.56% (prev 12.59%)
Tobins Q-Ratio = 0.66 (Enterprise Value 9.48b / Total Assets 14.41b)
Interest Expense / Debt = 1.86% (Interest Expense 152.7m / Debt 8.21b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 302.5m (EBIT 403.3m * (1 - 25.00%))
Current Ratio = 0.70 (Total Current Assets 2.09b / Total Current Liabilities 2.98b)
Debt / Equity = 2.29 (Debt 8.21b / totalStockholderEquity, last quarter 3.59b)
Debt / EBITDA = 3.93 (Net Debt 7.46b / EBITDA 1.90b)
Debt / FCF = 11.38 (Net Debt 7.46b / FCF TTM 655.2m)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.59% (Net Income -86.6m / Total Assets 14.41b)
RoE = -2.43% (Net Income TTM -86.6m / Total Stockholder Equity 3.56b)
RoCE = 5.87% (EBIT 403.3m / Capital Employed (Equity 3.56b + L.T.Debt 3.31b))
RoIC = 2.58% (NOPAT 302.5m / Invested Capital 11.71b)
WACC = 2.00% (E(1.36b)/V(9.57b) * Re(5.63%) + D(8.21b)/V(9.57b) * Rd(1.86%) * (1-Tc(0.25)))
Discount Rate = 5.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 56.34%
[DCF Debug] Terminal Value 87.43% ; FCFF base≈580.8m ; Y1≈653.7m ; Y5≈877.1m
Fair Price DCF = 51.55 (EV 25.83b - Net Debt 7.46b = Equity 18.38b / Shares 356.5m; r=5.90% [WACC]; 5y FCF grow 14.61% → 2.90% )
EPS Correlation: -54.25 | EPS CAGR: -38.77% | SUE: 0.0 | # QB: 0
Revenue Correlation: 37.27 | Revenue CAGR: 29.64% | SUE: 1.74 | # QB: 1
EPS next Year (2026-12-31): EPS=0.20 | Chg30d=-0.011 | Revisions Net=-2 | Growth EPS=+66.3% | Growth Revenue=+4.4%